Printer Friendly

CYTOGEN AND CETUS ANNOUNCE DENMARK APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT

 CYTOGEN AND CETUS ANNOUNCE DENMARK APPROVES
 ONCOSCINT(R) CR103 CANCER IMAGING AGENT
 PRINCETON, N.J., Dec. 5 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) and Cetus Corporation (NASDAQ: CTUS), Emeryville, Calif., announced today that the Danish National Board of Health has granted marketing approval to OncoScint(R) CR103, a monoclonal antibody-based imaging agent for colorectal cancer.
 Denmark is the fifth member country of the European Community (EC) to grant approval following last June's recommendation of the Committee for Proprietary Medicinal Products (CPMP), the central regulatory body of the EC. The use of OncoScint is expected to aid in the detection, staging, and follow-up of patients with new or recurrent colorectal cancer. Germany, Luxembourg, the Netherlands and the United Kingdom have previously granted approval.
 In the United States, a Product License Application for OncoScint CR103, colorectal, was submitted to the Food and Drug Administration in September 1989 and is currently under active review.
 Founded in 1971, Cetus Corporation applies the tools of biotechnology and science of immunology to the development of novel pharmaceutical products. Cetus' European subsidiary, EuroCetus, is based in Amsterdam, Netherlands, and currently operates sales offices in France, Spain, Germany, Italy, and the United Kingdom.
 Cytogen Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies in order to optimize the function of the antibody as a delivery vehicle. The company currently has six cancer imaging agents under development and two of these imaging agents, for colorectal and ovarian cancer, are awaiting FDA approval. Also in clinical trials are two cancer therapy agents.
 /delval/
 -0- 12/5/91
 /CONTACT: Laura M. Hahn of Cytogen, 609-987-8221, or Katherine A. Russell of Cetus, 510-420-3227/
 (CYTO CTUS) CO: Cytogen Corporation; Cetus Corporation ST: New Jersey, California IN: MTC SU:


CC -- PH021 -- 9708 12/05/91 13:21 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 5, 1991
Words:303
Previous Article:KCS GROUP SETS STOCK SPLIT, FIRST DIVIDEND PAYMENT
Next Article:WOODCREST DEVELOPMENT ANNOUNCES CONSOLIDATION OF REGIONAL OFFICES
Topics:


Related Articles
CYTOGEN AND CETUS ANNOUNCE UNITED KINGDOM AND THE NETHERLANDS APPROVALS FOR ONCOSCINT CR103 CANCER IMAGING AGENT
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING BREAST CANCER
CYTOGEN AND CETUS ANNOUNCE SPAIN APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT
CYTOGEN AND CHIRON ANNOUNCE ITALY APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT
CYTOGEN CORPORATION ANNOUNCES FOURTH QUARTER RESULTS
FDA APPROVES ONCOSCINT AND INDICLOR FOR COLORECTAL AND OVARIAN CANCER DETECTION; FIRST CANCER IMAGING AGENT BASED ON A MONOCLONAL ANTIBODY
CYTOGEN CORPORATION ANNOUNCES ESTIMATED FOURTH QUARTER RESULTS
CYTOGEN ANNOUNCES REVISION OF STRATEGIC PLAN
CYTOGEN AND CYTORAD REPORT FAVORABLE RESULTS IN PROSTATE CANCER IMAGING
CYTOGEN: FDA APPROVES ONCOSCINT(TM) CR/OV FOR REPEAT ADMINISTRATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters